bionity.com

Last year our editorial team has put their heart ❤️ and soul into creating a series of unique 👉 market overviews for users in the #laboratory, #process and #analytics industries – the broadest compilation of its kind ever. 𝗢𝘂𝗿 𝗮𝗶𝗺 𝗶𝘀 𝘁𝗼 𝘀𝗶𝗺𝗽𝗹𝗶𝗳𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝘀 𝗳𝗼𝗿 𝘆𝗼𝘂 𝗮𝗻𝗱 𝘆𝗼𝘂𝗿 𝗰𝗼𝗹𝗹𝗲𝗮𝗴𝘂𝗲𝘀 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱.   That’s why we’re delighted to present the fruits of our endeavors in this special newsletter: the world's largest market overviews of #HPLC systems, #NIR and #UVVis spectrometers, #particleanalyzers and #massspectrometers.   It takes only three simple steps to find the right solution for your application: 1. Select products or suppliers; 2. Send inquiry; 3. Receive offer. For Example the Market Overview: 𝗛𝗣𝗟𝗖 𝘀𝘆𝘀𝘁𝗲𝗺𝘀: 𝗠𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟮𝟬 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗳𝗿𝗼𝗺 𝟯𝟯 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿𝘀 👇 https://lnkd.in/erRpdv-H ThermoFisher, labomatic, Agilent, Bruker and many more ... the world's largest market overview for HPLC/UHPLC systems features all the manufacturers. You’ll discover suitable solutions for your application in next to no time.  Nowhere else will you find such a comprehensive overview spanning 120+ HPLC systems, filterable by useful criteria such as flow rate and maximum pressure. 𝗦𝗲𝗲 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿𝘀𝗲𝗹𝗳! 𝗢𝗻𝗲 𝗖𝗹𝗶𝗰𝗸 𝘁𝗼 𝘁𝗵𝗲 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄. 👇 https://lnkd.in/erRpdv-H

𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺 𝗔𝗰𝗾𝘂𝗶𝗿𝗲𝘀 𝗧𝗮𝗿𝗴𝗲𝘁 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 #𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗼𝗳 𝗚𝗹𝘆𝗰𝗼𝘁𝗼𝗽𝗲: Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH. The deal encompasses a portfolio of preclinical antibodies against multiple oncology targets that can be developed into radiopharmaceuticals. It also includes Glycotope’s laboratories, cell banks, tumor target data base, and the equipment needed to exploit the discovery platform, along with a range of patents, licenses, and other tangible assets. In total, Pentixapharm will be able to add an integrated team of 40 seasoned executives, R&D specialists, and administrators to its staff. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/ebW6ZMei Hakim Bouterfa, Andreas Eckert

"𝗦𝗹𝗲𝗲𝗽 𝘁𝗶𝗺𝗲𝗿" 𝗳𝗼𝗿 𝗶𝗺𝗺𝘂𝗻𝗲 𝗰𝗲𝗹𝗹𝘀 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱: In chronic hepatitis B, the liver contains immune cells that could destroy #hepatitis B virus-infected cells but are inactive. A team from the Technical University of Munich (TUM) has discovered that cells in blood vessels in the liver start a “sleep timer” that switches off immune cells. Targeting this mechanism could be a starting point for immunotherapies. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eP4xEDRK TUM, Percy A. Knolle, Miriam Bosch

𝗛𝗲𝗽𝗮𝗥𝗲𝗴𝗲𝗻𝗶𝗫 𝗿𝗮𝗶𝘀𝗲𝘀 €𝟭𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗿𝗼𝘂𝗻𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗛𝗥𝗫-𝟮𝟭𝟱 𝗳𝗼𝗿 𝗹𝗶𝘃𝗲𝗿 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻: HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and HTGF | High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the company’s clinical candidate HRX-215. As part of the financing, Fabienne Roussel, Partner at Vesalius Biocapital, joins the Non-Executive Board of Directors. Elias Papatheodorou will become Chief Executive Officer, moving from Chair of the Board. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eiB8C_qa Linda Greenbaum, Tobias Jacob

𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 𝘁𝗵𝗲 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗳 𝗹𝗶𝗳𝗲 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗼𝘅𝘆𝗴𝗲𝗻: The “#AnoxyGen” project will decode novel active substances of anaerobes and elucidate their role in nature. Some of these could be useful for humans, animals and the environment. Christian Hertweck has been awarded one of the ERC Advanced Grants by the European Research Council (ERC). In the project, he wants to investigate the unique biosynthetic pathways and active compounds of anaerobic bacteria in order to better understand their role in nature and make them usable for medical, ecological and biotechnological applications. Hertweck heads the Department of Biomolecular Chemistry at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI) and is Professor of Natural Product Chemistry at Friedrich Schiller University Jena. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/e3UAuuum Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut, Friedrich-Schiller-Universität Jena

𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 #𝗯𝗶𝗼𝗹𝗲𝗮𝗰𝗵��𝗻𝗴 𝗼𝗳 𝗰𝗼𝗽𝗽𝗲𝗿, 𝗶𝗻𝗱𝗶𝘂𝗺 𝗮𝗻𝗱 𝘇𝗶𝗻𝗰 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱: Microorganisms work in an underground bioreactor and convert ores or residual materials from mining into the valuable metals copper, indium and zinc. Innovative membrane filters then filter the valuable metals from the resulting process water. In a pilot plant of a current mining project near Pöhla in Saxony, a team from the TU Bergakademie Freiberg wants to combine both procedures into an innovative process. The environmentally friendly solution could make it possible to extract metals at low temperatures and directly in a mine using a process known as bioleaching. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eYeVZXbT

𝗔 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 #𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 #𝗜𝗻𝘀𝘂𝗹𝗶𝗻: Up to three percent of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the body in a masked form - in the form of tiny nanoparticles. The insulin is only released in the target organ when the pH value deviates from the slightly alkaline environment in the blood. The molecular transport system could also serve as a platform for releasing other drugs in the body precisely at the target site. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/ekG8GD_X Anastasiia Murmiliuk, Aurel Radulescu, Jülich Centre for Neutron Science (JCNS), Shilpa Mohanakumar, Kathy Wood, Kuno Schwärzer, Dr. Martin Dulle, thomas gensch, Kanae Ito, Stephan Förster

𝗙𝘂𝘁𝘂𝗿𝗲 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 𝗣𝗿𝗶𝘇𝗲 𝟮𝟬𝟮𝟰 𝗔𝘄𝗮𝗿𝗱𝗲𝗱 𝘁𝗼 𝗟𝗮𝘂𝗿𝗲𝗻 𝗚𝗮𝗿𝗱𝗻𝗲𝗿: Merck KGaA, Darmstadt, Germany, awarded Professor Lauren Gardner, representing Johns Hopkins University, Baltimore, USA, with the Future Insight Prize 2024 worth € 500,000 for her contributions to develop advanced artificial intelligence (AI) systems to help quickly discover and control future pandemics. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/epq5CjWJ The Johns Hopkins University

𝗙𝗮𝘀𝘁𝗲𝗿 #𝗻𝗲𝘂𝗿𝗼𝗯𝗼𝗿𝗿𝗲𝗹𝗶𝗼𝘀𝗶𝘀 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝘂𝘀𝗶𝗻𝗴 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀: Anewly defined threshold for the concentration of the cytokine CXCL13 may improve the diagnosis of neuroborreliosis. The clinical diagnosis of this disease, which is caused by infections from tick bites, is still difficult and often occurs long after infection. CXCL13 now makes it possible to diagnose neuroborreliosis more quickly and start treatment earlier. In the study conducted by the Karl Landsteiner University of Health Sciences (KL Krems), a concentration of CXCL13 in the cerebrospinal fluid of > 271 pg/ml was identified with a very high statistical certainty as the threshold value for a better diagnosis of neuroborreliosis. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dKAMZwWN Karl Landsteiner Institut für Human Factors und Human Resources im Gesundheitswesen , Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, Universitätsklinikum St. Pölten, Eva Maria Gruber, Barbara Maria Christina Bauder

𝗡𝗲𝘄 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗼𝗻 𝗳𝗲𝗺𝗮𝗹𝗲 #𝗳𝗲𝗿𝘁𝗶𝗹𝗶𝘁𝘆: Female mammals – including humans – are born with all of their egg #cells. Of a woman’s one to two million egg cells, about 400 mature before menopause and can be fertilized. Some egg cells therefore survive for several decades – and need to remain functional over this long time. Extremely long-lived proteins in the ovary seem to play an important role in this, as teams of researchers from Göttingen (Germany) have now discovered in experiments with mice. These long-lived proteins appear to help maintain fertility for as long as possible. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/d_fvNCQS Max Planck Institute, Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Melina Schuh, Juliane Liepe, Henning Urlaub